InvestSMART

Syntara Limited (ASX: SNT) - Announcements

- Current share price for SNT : $0.025

ASX company news and announcements for Syntara Limited (SNT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Syntara Limited (SNT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Syntara Limited (SNT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Syntara Limited (SNT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$49 Investor Presentation Canaccord Drug & Device Conference 13 Oct 2026 8:43AM $0.025 $0.025 fallen by 0%
$49 Further significant results from SNT-4728 iRBD Phase 2 trial 7 Oct 2026 9:32AM $0.020 $0.025 risen by 25%
$49 Notification regarding unquoted securities - SNT 5 Oct 2026 2:24PM $0.021 $0.025 risen by 19.05%
$49 Notification regarding unquoted securities - SNT 5 Oct 2026 2:21PM $0.021 $0.025 risen by 19.05%
$49 Syntara expands SNT-9465 skin scarring study 1 Oct 2026 9:49AM $0.022 $0.025 risen by 13.64%
$49 Syntara receives A$4.7m R&D Tax Incentive 21 Sep 2026 8:45AM $0.023 $0.025 risen by 8.70%
$49 Application for quotation of securities - SNT 15 Sep 2026 10:01AM $0.024 $0.025 risen by 4.17%
$49 Notification of 2026 AGM Date 15 Sep 2026 9:58AM $0.024 $0.025 risen by 4.17%
$49 Appendix 4G and Corporate Governance Statement 27 Aug 2026 2:50PM $0.027 $0.025 fallen by 7.41%
$49 Appendix 4E and Annual Report 27 Aug 2026 2:49PM $0.027 $0.025 fallen by 7.41%
$49 Investor Update Webinar Presentation 28 Jul 2026 11:01AM $0.023 $0.025 risen by 8.70%
$49 Investor Update Webinar 27 Jul 2026 9:56AM $0.022 $0.025 risen by 13.64%
$49 Investor Presentation 27 Jul 2026 9:26AM $0.022 $0.025 risen by 13.64%
$49 Quarterly Activities/Appendix 4C Cash Flow Report 27 Jul 2026 9:18AM $0.022 $0.025 risen by 13.64%
$49 AZALOX MDS study advances to final Phase 1b cohort 20 Jul 2026 10:01AM $0.023 $0.025 risen by 8.70%
$49 SNT-4728 Webinar Presentation 6 Jul 2026 1:13PM $0.024 $0.025 risen by 4.17%
$49 Encouraging SNT-4728 Phase 2 iRBD results 6 Jul 2026 9:43AM $0.023 $0.025 risen by 8.70%
$49 Trading Halt 3 Jul 2026 9:23AM $0.023 $0.025 risen by 8.70%
$49 Notification regarding unquoted securities - SNT 2 Jul 2026 3:14PM $0.023 $0.025 risen by 8.70%
$49 Application for quotation of securities - SNT 2 Jul 2026 2:59PM $0.022 $0.025 risen by 13.64%
$49 Proposed issue of securities to the CEO 2 Jul 2026 2:56PM $0.022 $0.025 risen by 13.64%
$49 SNT-9465 scarring trial exceeds 50% enrolment 1 Jul 2026 10:01AM $0.021 $0.025 risen by 19.05%
$49 Change in substantial holding 30 Jun 2026 9:36AM $0.020 $0.025 risen by 25%
$49 Section 708A(5)(e) notice 25 Jun 2026 9:18AM $0.023 $0.025 risen by 8.70%
$49 Application for quotation of securities - SNT 25 Jun 2026 9:12AM $0.023 $0.025 risen by 8.70%

1 - 25 of 282 results

Page 1 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.